NO20012108L - Kromenon- og kromanonderivater som integrininhibitorer - Google Patents

Kromenon- og kromanonderivater som integrininhibitorer

Info

Publication number
NO20012108L
NO20012108L NO20012108A NO20012108A NO20012108L NO 20012108 L NO20012108 L NO 20012108L NO 20012108 A NO20012108 A NO 20012108A NO 20012108 A NO20012108 A NO 20012108A NO 20012108 L NO20012108 L NO 20012108L
Authority
NO
Norway
Prior art keywords
chromenone
integrin inhibitors
chromone derivatives
chromone
derivatives
Prior art date
Application number
NO20012108A
Other languages
English (en)
Other versions
NO20012108D0 (no
Inventor
Claus Fittschen
Simon Goodman
Joachim Maerz
Peter Raddatz
Matthias Wiesner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20012108L publication Critical patent/NO20012108L/no
Publication of NO20012108D0 publication Critical patent/NO20012108D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
NO20012108A 1998-10-30 2001-04-27 Kromenon- og kromanonderivater som integrininhibitorer NO20012108D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19850131A DE19850131A1 (de) 1998-10-30 1998-10-30 Chromenon- und Chromanonderivate
PCT/EP1999/007725 WO2000026212A1 (de) 1998-10-30 1999-10-14 Chromenon- und chromanonderivate als integrinhemmer

Publications (2)

Publication Number Publication Date
NO20012108L true NO20012108L (no) 2001-04-27
NO20012108D0 NO20012108D0 (no) 2001-04-27

Family

ID=7886203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012108A NO20012108D0 (no) 1998-10-30 2001-04-27 Kromenon- og kromanonderivater som integrininhibitorer

Country Status (21)

Country Link
US (1) US6849646B1 (no)
EP (1) EP1124824B1 (no)
JP (1) JP4511734B2 (no)
KR (1) KR20010080896A (no)
CN (1) CN1150189C (no)
AR (1) AR021029A1 (no)
AT (1) ATE370944T1 (no)
AU (1) AU754280B2 (no)
BR (1) BR9914893A (no)
CA (1) CA2348391C (no)
CZ (1) CZ20011515A3 (no)
DE (2) DE19850131A1 (no)
ES (1) ES2292252T3 (no)
HU (1) HUP0104800A3 (no)
ID (1) ID28482A (no)
NO (1) NO20012108D0 (no)
PL (1) PL347246A1 (no)
RU (1) RU2234505C2 (no)
SK (1) SK5532001A3 (no)
WO (1) WO2000026212A1 (no)
ZA (1) ZA200104411B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
ATE415163T1 (de) 2000-11-01 2008-12-15 Merck Patent Gmbh Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
RU2294192C2 (ru) * 2001-05-30 2007-02-27 Дзе Скриппс Рисерч Инститьют Система доставки нуклеиновых кислот
AU2002319282B2 (en) 2001-08-01 2007-06-28 Merck Patent Gmbh Integrin inhibitors for the treatment of eye diseases
US20050085415A1 (en) * 2002-02-14 2005-04-21 Matthias Wiesner Methods and compositions for the treatment of eye diseases
NZ536190A (en) 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
AU2003245935A1 (en) * 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE10337863A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
CN103450138B (zh) * 2008-06-25 2015-04-08 阵列生物制药公司 制备6-取代的苯氧基色满羧酸衍生物的中间体
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
RU2612875C1 (ru) * 2015-12-14 2017-03-13 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Средство для ингибирования фермента тирозил-днк-фосфодиэстеразы 1 человека
CN112110902B (zh) * 2020-09-17 2021-12-07 江苏科技大学 1-脱氧野尻霉素-山奈酚化合物、中间体，制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89840A (en) * 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
AU634994B2 (en) * 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
EP0525123B1 (en) * 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
FR2693196B1 (fr) * 1992-07-03 1994-12-23 Lipha Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
FR2717479B1 (fr) * 1994-03-18 1996-06-07 Pf Medicament Nouvelles 3-(omega-benzoylpipéridino) alcoyl)-4H-Benzopyran-4-ones, leur préparation et leur application en thérapeutique.

Also Published As

Publication number Publication date
RU2234505C2 (ru) 2004-08-20
ZA200104411B (en) 2002-08-29
DE59914471D1 (de) 2007-10-04
JP4511734B2 (ja) 2010-07-28
EP1124824B1 (de) 2007-08-22
AU754280B2 (en) 2002-11-14
US6849646B1 (en) 2005-02-01
AU6471699A (en) 2000-05-22
BR9914893A (pt) 2001-07-17
CN1150189C (zh) 2004-05-19
CN1329610A (zh) 2002-01-02
HUP0104800A2 (hu) 2002-07-29
HUP0104800A3 (en) 2003-12-29
ES2292252T3 (es) 2008-03-01
DE19850131A1 (de) 2000-05-04
AR021029A1 (es) 2002-06-12
WO2000026212A1 (de) 2000-05-11
ATE370944T1 (de) 2007-09-15
JP2002528544A (ja) 2002-09-03
CA2348391A1 (en) 2000-05-11
CA2348391C (en) 2009-09-29
SK5532001A3 (en) 2001-12-03
KR20010080896A (ko) 2001-08-25
EP1124824A1 (de) 2001-08-22
PL347246A1 (en) 2002-03-25
ID28482A (id) 2001-05-31
NO20012108D0 (no) 2001-04-27
CZ20011515A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
DK1097127T3 (da) Diacylhydrazinderivater som integrininhibitorer
NO986090D0 (no) Fenylalaninderivater som integrininhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20012116L (no) Vitamin D analoger
NO20006293D0 (no) Nye benzopyran eller tiobenzopyranderivater
NO992725L (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
NO20012108D0 (no) Kromenon- og kromanonderivater som integrininhibitorer
PT1070059E (pt) Derivados de cromanona e tiocromanona
EE200000140A (et) Asendatud kromaani derivaadid
NO994510D0 (no) Substituerte isokinolin-derivater og deres anvendelse som antikonvulsanter
EE200000144A (et) Asendatud kromaani derivaadid
NO20032754L (no) Urea- og/eller uretanderivater som integrininhibitorer
PT1140890E (pt) Derivados de cromano
DK1212316T3 (da) Benzopyraner og benzothiopyraner som RAR-selektive retinoidagonister
ATE272046T1 (de) O-substituierte 6-methyl-tramadol-derivate
NO20015652D0 (no) 1-trifluorometyl-4-hydroksy-7-piperidinyl- aminometylkromanderivater
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DK1200409T3 (da) Substituerede isoquinolinderivater og deres anvendelse som krampestillende midler
DK1077945T3 (da) Isoquinoliner som urokinaseinhibitorer
NO20011654D0 (no) Benzamidderivater som trombininhibitorer
ATE266631T1 (de) Imidamid-derivate
DE69930852D1 (de) Prenyltransferase-inhibitoren
DE59909479D1 (de) Imidamid-derivate
NO20020592D0 (no) Fluorenderivater som integrininhibitorer
DK1066284T3 (da) Benzo(C)quinolizinderivater og deres anvendelse som 5-alpha-reduktaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application